Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease

Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Akram, Qasim, Roberts, Mark, Oddis, Chester, Herrick, Arianne, Chinoy, Hector
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847324/
https://www.ncbi.nlm.nih.gov/pubmed/27407275
http://dx.doi.org/10.5114/reum.2016.58760
_version_ 1782429193299034112
author Akram, Qasim
Roberts, Mark
Oddis, Chester
Herrick, Arianne
Chinoy, Hector
author_facet Akram, Qasim
Roberts, Mark
Oddis, Chester
Herrick, Arianne
Chinoy, Hector
author_sort Akram, Qasim
collection PubMed
description Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease. We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients.
format Online
Article
Text
id pubmed-4847324
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
record_format MEDLINE/PubMed
spelling pubmed-48473242016-07-12 Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease Akram, Qasim Roberts, Mark Oddis, Chester Herrick, Arianne Chinoy, Hector Reumatologia Case Report Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease. We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients. Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016-03-24 2016 /pmc/articles/PMC4847324/ /pubmed/27407275 http://dx.doi.org/10.5114/reum.2016.58760 Text en Copyright © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016 http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Case Report
Akram, Qasim
Roberts, Mark
Oddis, Chester
Herrick, Arianne
Chinoy, Hector
Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
title Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
title_full Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
title_fullStr Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
title_full_unstemmed Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
title_short Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
title_sort rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847324/
https://www.ncbi.nlm.nih.gov/pubmed/27407275
http://dx.doi.org/10.5114/reum.2016.58760
work_keys_str_mv AT akramqasim rituximabinducedneutropeniainapatientwithinflammatorymyopathyandsystemicsclerosisoverlapdisease
AT robertsmark rituximabinducedneutropeniainapatientwithinflammatorymyopathyandsystemicsclerosisoverlapdisease
AT oddischester rituximabinducedneutropeniainapatientwithinflammatorymyopathyandsystemicsclerosisoverlapdisease
AT herrickarianne rituximabinducedneutropeniainapatientwithinflammatorymyopathyandsystemicsclerosisoverlapdisease
AT chinoyhector rituximabinducedneutropeniainapatientwithinflammatorymyopathyandsystemicsclerosisoverlapdisease

Ejemplares similares